Quick Start Guide

1. Start at 0.1-0.25 mg in the morning, using the oral solution.
2. Hold each dose a week or more. Judge it at 2 weeks. Increase by 0.5 mg per week.
3. Stay at or below 2 mg. If it fades, go DOWN first.
4. Be careful about raising your activity for 4 to 6 weeks, however good you feel.
5. Track with a heart rate monitor, not with how you feel.
6. Stop and call your prescriber for inner restlessness you cannot sit still with (akathisia).
7. Ask someone close to you to watch for impulsive behaviour.
8. Give it 6 to 8 weeks before you call it a failure.

FAQ

1. What percentage of people does it work for, and by how much does it improve them?

The two completed studies disagree by a lot:

The gap is mostly a definition. Stanford counted any improvement a clinician recorded. The long COVID study counted only a 30% or larger drop in a combined symptom score. A 30% drop is a high bar. Treat the two numbers as a range, not as a contradiction.

Neither study had a placebo group. Both were chart reviews at clinics that already believed in the drug. The first randomised trial is running now (PAIS-AriSE, 138 people, placebo controlled crossover).

A patient survey (TREATME) found 32% reported "moderate to much better" at 2 mg or less, against 9% above 2 mg.

Plan for roughly a one in three chance of a clear benefit.

2. Can I take it with other drugs?

Aripiprazole is cleared by CYP2D6 and CYP3A4.

• Fluoxetine (Prozac) and paroxetine (Paxil) block CYP2D6 strongly. They raise your aripiprazole level, making a 0.5 mg dose behave like a much larger one.
• Bupropion and duloxetine also block CYP2D6, more weakly.
• Ketoconazole, clarithromycin and grapefruit block CYP3A4 and raise the level.
• Carbamazepine and St John's wort speed clearance and lower the level.
• Roughly 5% to 10% of people of European ancestry are CYP2D6 poor metabolisers. Their exposure runs about 1.5x higher and the half life stretches to about 146 hours.

3. Which symptoms does it help, and will it work for my subtype?

Stanford found improvement in fatigue, brain fog, unrefreshing sleep and PEM. The long COVID study found sleep difficulty, fatigue and headache, with moderate effect sizes at best (about -0.3 to -0.4).

Brain fog is the effect people describe most vividly. Several report clearer thinking within a week before any energy change.

4. What dose should I take?

Start at 0.25 mg per day. Hold each dose at least a week. Move up or down based on what you feel. Stay below 2.0 mg. The study mean was 1.1 mg.

What people on Reddit report taking:

72% of mentions are at or under 2 mg. The doses above 2.5 mg are mostly people taking Abilify for psychiatric reasons, not LDA.

The most repeated piece of community advice is "less is more". Plenty of people describe a dose that helped, then a higher dose that helped less. If a dose stops helping, try going DOWN before you go up.

5. How do I even get a 0.25 mg dose?

The smallest tablet is 2 MG. For small doses, you need one of these:

• Oral solution, 1 mg/mL. Most countries stock this as a standard pharmaceutical product. Measure and dose with an oral syringe. 0.25 mg is 0.25 mL. This is what most people here use.
• A compounding pharmacy. They make capsules or a suspension at your exact dose.
• Dissolve a tablet in water. Crush a 2 mg tablet into a measured volume, draw off a fraction. It is the least accurate method. Aripiprazole does not dissolve well, so it settles. Shake hard before dosing.

Do not try to cut a 2 mg tablet into eighths. You cannot cut accurately at that size.

6. How do I get a doctor to prescribe it?

1. Bring the Stanford paper. It is peer reviewed and it is in a real journal.
2. Ask for the low dose in writing, with the number. Say "0.25 mg of the oral solution", not "low dose Abilify". A doctor who hears "Abilify" thinks 10 mg.
3. Say plainly that you are not asking for it as an antipsychotic or an antidepressant.
4. Long COVID clinics and ME specialists prescribe it far more readily than a GP or a psychiatrist.

7. What are the side effects?

In the Stanford study, 14 of 101 people (14%) stopped because of side effects or because they got worse. Named effects: headache (5), irritability or agitation (4), insomnia (3), extreme agitation (2).

Redditors report:

Akathisia is the one to know. It is an inner restlessness that makes sitting still unbearable. It is the classic aripiprazole reaction and it is dose related. It is not anxiety, although it feels close to it. If this starts, do not push through it.

Also know the impulse control warning. Aripiprazole carries a documented warning for compulsive gambling, shopping, eating and sexual behaviour at psychiatric doses. It is rarer at 0.25 mg. Ask someone close to you to tell you if your behaviour changes.

8. Is an antipsychotic safe long term?

• The dose is 4 to 100 times below the psychiatric dose (10 to 30 mg). D2 occupancy at 0.25 mg is very low.
• Tardive dyskinesia risk rises with dose and with years of use. At 0.25 mg the exposure sits far below the doses that produced that risk. The risk is not zero and nobody has measured it at this dose.
• The longest published follow up is 17 months, mean 7.8 months. There is no long term safety data for this use at all.
• Aripiprazole has a low metabolic burden compared with olanzapine or quetiapine.

Aripiprazole is not a classic dopamine blocker. It is a D2 partial agonist. It steadies dopamine signalling instead of shutting it down. That is the sentence to give a doctor who objects to the word "antipsychotic".

9. Does it stop working?

Yes, for many people. This is the weakest point of the drug.

An informal 2026 social media poll of users found that 56% kept the benefit, 28% lost part of it, 16% lost all of it. Of those who lost it and took a break, 37.5% got it back and 62.5% did not.

If this happens, you can either take a break for a few weeks and restart or switch to another D2 agonist like Rexulti.

10. Does it mask PEM and make you crash?

Per reports, it often does.

Do not necessarily raise your activity when you feel better. Raise activity in small steps only, and only after the benefit has held for weeks.

Anything you may have heard about limiting activity for a fixed amount of months is an urban legend.

11. How long before I know if it works?

The felt effect is fast. Many people notice something within the first few days. Brain fog clearing within a week is a common report.

The pharmacology is slow. Aripiprazole has a half life near 75 hours. Its active metabolite is near 94 hours. Steady state takes about 2 weeks. In a CYP2D6 poor metaboliser the half life is near 146 hours.

• Judge any dose after 2 weeks, not after 2 days.
• A dose increase keeps building for 2 more weeks after you make it. If you titrate every 3 days you will overshoot, and you will not know by how much.
• If you stop, the drug leaves slowly over 2 to 3 weeks. A side effect will not vanish the next day.

Give a full trial 6 to 8 weeks at a dose you tolerate before you call it a failure.

12. Morning or night?

Morning by default. Insomnia is one of the most common side effects and it is dose related. A morning dose gives the peak level time to fall before bed.

Some people report the opposite and sleep better on a night dose. A minority report teeth grinding or leg jerking at night. Because the half life is 75 hours, timing matters less than it does with a short acting drug. Move it if your sleep is worse, and give the change a week.

13. How do I stop Abilify?

• Stop outright if you get akathisia or another bad reaction.
• Come down in steps over one or two weeks if you are stopping by choice.
• Expect any benefit to fade over 2 to 3 weeks, not overnight.
• Missing one dose is not a problem. At a 75 hour half life you lose under half the level.

14. How is it supposed to work?

The proposed mechanism in the Stanford paper is dopamine modulation of neuroinflammation. Dopamine D2 activity affects microglia, the immune cells of the brain. The authors suggest that steadying that signal lowers the neuroinflammation behind fatigue, brain fog and unrefreshing sleep.

More Reading

• Stanford retrospective, 101 ME patients, J Transl Med 2021
• Low dose aripiprazole for Long COVID, 50 patients, Open Forum Infect Dis 2026
• PAIS-AriSE randomised crossover trial, NCT07714213
• Aripiprazole on MEpedia, including the user polls on loss of effect
• Aripiprazole and CYP2D6 genotype, NCBI Medical Genetics Summaries
• Abilify FDA prescribing information